Holly Valdiviez joined Acadia in April 2022 and leads the sales organization supporting the NUPLAZID® (pimavanserin) brand.
With more than 25 years of experience in the healthcare industry, Ms. Valdiviez is an accomplished executive in the neuroscience field. She has experience launching multiple CNS medications, including ABILIFY®, Abilify Maintena®, Rexulti® and Aimovig®, and building high-performing sales teams.
Ms. Valdiviez has also held leadership roles in marketing and business operations. She has held roles of increasing responsibility at Bristol Myers Squibb, Amgen and Otsuka America Pharmaceutical, Inc. and most recently at Adamas Pharmaceuticals, Inc., where she energized their sales organization, dedicated to advancing the care of people with Parkinson’s disease.
Ms. Valdiviez received her Bachelor of Arts degree in Business and Corporate Communication from Buena Vista University in Storm Lake, Iowa.